Treats asthma. Sold as Serevent. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 2 applications for Salmeterol Xinafoate (sold as Serevent), first approved Feb 4, 1994, with 6 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Serevent Diskus | Part D | $32.9M | -10% | 13,625 |
| Safety and Efficacy Comparison Between CHF5993 100/6 12.5µg pMDI to Seretide Evohaler 125/25µg pMDI in Adolescent Subjects With AsthmaAsthma · Chiesi Farmaceutici S.p.A. | Phase 3 | Not yet recruiting | Oct 5, 2026 |
| Boosting Referrals to Asthma Specialists for Patients Seen at the Emergency Room for an Asthma ExacerbationAsthma Attack, Asthma Control · Juan Carlos Cardet | Not applicable | Recruiting | Feb 9, 2026 |
| Vibroacoustic Therapy With Oscillating Positive Expiratory Pressure in the Treatment of Nasal CongestionAtopic Rhinitis, Atopic Asthma · Second Affiliated Hospital, Zhejiang University, School of Medicine | Not applicable | Not yet recruiting | Aug 11, 2025 |
| Acupuncture for Persistent Dyspnea Despite Medical Treatment in COPDCOPD (Chronic Obstructive Pulmonary Disease), Acupuncture · Istanbul Medeniyet University | Not applicable | Active, not recruiting | Jul 10, 2025 |
| Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk AsthmaAsthma · Sanofi | Phase 2 | Active, not recruiting | Nov 6, 2024 |
| Urinary Concentration After SalmeterolHealthy · University of Copenhagen | Not applicable | Recruiting | Oct 24, 2024 |
| Salmeterol Effect on Exercise PerformanceHealthy · University of Copenhagen | Not applicable | Recruiting | Oct 23, 2024 |
| Muscle Anabolic Response to β2-adrenergic Stimulation With Increased Amino Acid Availability.Healthy · University of Copenhagen | Not applicable | Recruiting | Oct 23, 2024 |
| Feb 4, 1994 | SereventNDA 20236 · New molecular entity | Glaxosmithkline | 19 | Discontinued |
| Sep 19, 1997 | SereventNDA 20692 · New dosage form | Glaxosmithkline | 35 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA